全文获取类型
收费全文 | 9895篇 |
免费 | 595篇 |
国内免费 | 81篇 |
专业分类
耳鼻咽喉 | 69篇 |
儿科学 | 254篇 |
妇产科学 | 263篇 |
基础医学 | 1371篇 |
口腔科学 | 142篇 |
临床医学 | 766篇 |
内科学 | 2571篇 |
皮肤病学 | 122篇 |
神经病学 | 1435篇 |
特种医学 | 388篇 |
外科学 | 870篇 |
综合类 | 16篇 |
一般理论 | 3篇 |
预防医学 | 453篇 |
眼科学 | 129篇 |
药学 | 762篇 |
中国医学 | 10篇 |
肿瘤学 | 947篇 |
出版年
2024年 | 26篇 |
2023年 | 168篇 |
2022年 | 287篇 |
2021年 | 493篇 |
2020年 | 266篇 |
2019年 | 378篇 |
2018年 | 414篇 |
2017年 | 308篇 |
2016年 | 368篇 |
2015年 | 381篇 |
2014年 | 545篇 |
2013年 | 623篇 |
2012年 | 820篇 |
2011年 | 857篇 |
2010年 | 491篇 |
2009年 | 445篇 |
2008年 | 626篇 |
2007年 | 573篇 |
2006年 | 563篇 |
2005年 | 491篇 |
2004年 | 354篇 |
2003年 | 301篇 |
2002年 | 268篇 |
2001年 | 45篇 |
2000年 | 39篇 |
1999年 | 55篇 |
1998年 | 45篇 |
1997年 | 36篇 |
1996年 | 36篇 |
1995年 | 24篇 |
1994年 | 24篇 |
1993年 | 15篇 |
1992年 | 16篇 |
1991年 | 24篇 |
1990年 | 20篇 |
1989年 | 23篇 |
1988年 | 25篇 |
1987年 | 14篇 |
1986年 | 14篇 |
1985年 | 8篇 |
1984年 | 7篇 |
1983年 | 7篇 |
1982年 | 3篇 |
1981年 | 8篇 |
1980年 | 4篇 |
1979年 | 8篇 |
1978年 | 5篇 |
1967年 | 3篇 |
1966年 | 3篇 |
1961年 | 2篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
Prognostic value of CD40 in adult soft tissue sarcomas. 总被引:4,自引:0,他引:4
Alessandro Ottaiano Anna De Chiara Francesco Perrone Gerardo Botti Flavio Fazioli Vincenzo De Rosa Nicola Mozzillo Vincenzo Ravo Brunello Morrica Ciro Gallo Carmela Pisano Maria Napolitano Paolo Antonio Ascierto Rosario Vincenzo Iaffaioli Gaetano Apice 《Clinical cancer research》2004,10(8):2824-2831
PURPOSE: The purpose is to evaluate the expression of CD40, a membrane protein predominantly expressed on B cells, dendritic cells, and macrophages, in a series of adult soft tissue sarcomas and to test its possible prognostic value. EXPERIMENTAL DESIGN: CD40 expression was studied by immunohistochemistry. Correlations with other baseline characteristics of patients and tumors were analyzed with chi(2) test. The prognostic value was studied with univariable and multivariable analysis adjusted by age, sex, tumor size, grade, location, and distant metastases. RESULTS: Eighty-two patients, between January 1994 and May 2001, were analyzed. Membrane or cytoplasmic staining for CD40 protein was absent in 30% of the tumors but present in <10% of cells in 22 (27%), in 10% to 50% in 23 (28%), and in >50% of cells in 12 (15%) tumors. There was no correlation between CD40 expression and age, sex, size, grade, and location of the primary tumor and distant metastases. With 61 patients (74.4%) progressed and 31 (37.8%) dead, CD40 expression was a significant prognostic factor for disease-free and overall survival at univariable and multivariable analysis. Patients with tumors expressing CD40 in >50% of cells had a dramatically unfavorable prognosis with median disease-free and overall survival of 7 and 17 months, respectively, and hazard ratios of relapse and death as compared with patients with CD40-negative tumors of 2.89 (95% confidence interval: 1.26-6.60) and 6.92 (95% confidence interval: 2.18-22.0), respectively. CONCLUSIONS: These data suggest that expression of CD40 protein in >50% of cells might indicate an unfavorable prognosis in adult soft tissue sarcomas. 相似文献
72.
Chiara Corsini Patrizia Mancuso Saki Paul Alessandra Burlini Giovanni Martinelli Giancarlo Pruneri Francesco Bertolini 《Clinical cancer research》2003,9(5):1820-1825
PURPOSE: Stroma cells play a relevant role in tumor development and progression. We investigated the activity of herceptin (HER), a humanized monoclonal antibody widely used for the treatment of HER2-overexpressing epithelial cancer, toward stroma cell lines L87/4 and L88/5. EXPERIMENTAL DESIGN: We studied the antiproliferative potential of HER and role of human serum in HER activity. We also investigated the ability of HER to alter ancillary functions of L87/4 and L88/5, such as support to long-term hematopoiesis, growth factor production, breast cancer cell adhesion, and proliferation. RESULTS: Flow cytometry showed that HER2 membrane expression in L87/4 and L88/5 stroma cells was intermediate between the expression in HER2-negative/dim MCF-7 breast cancer cells and HER2-bright SK-BC3 breast cancer cells. HER2 gene amplification was not detected by fluorescence in situ hybridization in either stromal cell lines. HER significantly inhibited L87/4 and L88/5 proliferation. Mean ID(50)s were found to be 2000 and 1700 micro g/ml for L87/4 and L88/5, respectively, after 3-day exposure and 800 micro g/ml for both cell lines after 9-day exposure. The presence of 10% human serum in the culture increased HER inhibitory activity. IC(50) of stroma cells was found to be intermediate between HER2-bright breast cancer cells (SK-BC3) and HER2-negative/dim breast cancer cells (MCF-7). The drug did not significantly affect the ability of stroma cells to support long-term hematopoiesis in the cobblestone area forming cell assay. In contrast, in coculture assay, MCF7 cells demonstrated a worse adhesion and growth capability on HER-treated stroma layers when compared with untreated stroma. Moreover, HER significantly reduced vascular endothelial growth factor production by L88/5 cells. CONCLUSIONS: Our data support the novel finding that HER may have a relevant activity against stroma cells. 相似文献
73.
Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models. 总被引:7,自引:0,他引:7
Fabio Pastorino Chiara Brignole Danilo Marimpietri Gabriella Pagnan Adriana Morando Domenico Ribatti Sean C Semple Claudio Gambini Theresa M Allen Mirco Ponzoni 《Clinical cancer research》2003,9(12):4595-4605
PURPOSE: Melanoma is a highly malignant and increasingly common tumor. Because the cure rate of metastatic melanoma by conventional treatment is very low, new therapeutic approaches are needed. We previously reported that coated cationic liposomes (CCL) targeted with a monoclonal antibody against the disialoganglioside (GD(2)) and containing c-myb antisense oligodeoxynucleotides (asODNs) resulted in a selective inhibition of the proliferation of GD(2)-positive neuroblastoma cells in vitro. EXPERIMENTAL DESIGN: Here, we tested the in vivo antitumor effects of this novel antisense liposomal formulation by targeting the c-myc oncogene on melanoma, a neuroectodermal tumor sharing with neuroblastoma the expression of GD(2). RESULTS: Our methods produced GD(2)-targeted liposomes that stably entrapped 90% of added c-myc asODNs. These liposomes showed a selective binding for GD(2)-positive melanoma cells in vitro. Melanoma cell proliferation was inhibited to a greater extent by GD(2)-targeted liposomes containing c-myc asODNs (aGD(2)-CCL-myc-as) than by nontargeted liposomes or free asODNs. The pharmacokinetic results obtained after i.v. injection of [(3)H]-myc-asODNs, free or encapsulated in nontargeted CCLs or GD(2)-targeted CCLs, showed that free c-myc-asODNs were rapidly cleared, with less than 10% of the injected dose remaining in blood at 30 min after injection. c-myc-asODNs encapsulated within either CCL or aGD(2)-CCL demonstrated a more favorable profile in blood, with about 20% of the injected dose of each preparation remaining in vivo at 24 h after injection. In an in vivo melanoma experimental metastatic model, aGD(2)-CCL-myc-as, at a total dose of only 10 mg of asODN per kilogram, significantly inhibited the development of microscopic metastases in the lung compared with animals treated with myc-asODNs, free or entrapped in nontargeted liposomes, or aGD(2)-CCL encapsulating scrambled asODNs (P < 0.01). Moreover, mice bearing established s.c. human melanoma xenografts treated with aGD(2)-CCL-myc-as exhibited significantly reduced tumor growth and increased survival (P < 0.01 versus control mice). The mechanism for the antitumor effects appears to be down-regulation of the expression of the c-myc protein and interruption of c-myc-mediated signaling: induction of p53 and inhibition of Bcl-2 proteins, leading to extensive tumor cell apoptosis. CONCLUSION: These results suggest that inhibition of c-myc proto-oncogene by GD(2)-targeted antisense therapy could provide an effective approach for the treatment of melanoma in an adjuvant setting. 相似文献
74.
Silvana Chiara Maria Teresa Nobile Maura Vincenti Rita Lionetto Alberto Gozza Maria Cristina Barzacchi Ornella Sanguineti Lazzaro Repetto Riccardo Rosso 《Cancer chemotherapy and pharmacology》1998,42(4):336-340
To evaluate toxicity and efficacy of chemotherapy in elderly patients (≥65 years of age) with advanced colorectal cancer,
data from two consecutive trials conducted between 1984 and 1995 at the National Institute for Cancer Research were analysed
comparing the results of treatment in those 65 years of age or older and in those younger than 65 years. Of 215 patients recruited,
82 elderly patients (median age 70 years, median performance status 1) received one of the following regimens based on 5-fluorouracil
(5-FU): (1) weekly 5-FU 600 mg/m2 i.v. bolus (30 patients); (2) weekly 5-FU 600 mg/m2 bolus plus leucovorin (LV) 500 mg/m2 2-h i.v. infusion (28 patients); (3) Weekly 5-FU 2600 mg/m2 24-h continuous i.v. infusion plus LV 100 mg 4-h i.v. infusion and 50 mg orally every 4 h for five doses (24 patients). Overall,
1071 chemotherapy cycles were administered with a median number of 12 courses per patient. The main side effects were diarrhoea,
observed in 38% of patients, stomatitis in 24% of patients and hand-foot syndrome in 13% of patients, and haematological toxicity
affected only 15% of patients. No patient suffered grade IV toxicity. In three patients chemotherapy was discontinued because
of toxicity (two patients suffered grade III diarrhoea, one patient grade III hand-foot syndrome). No significant difference
in toxicity was evident between patients older than or younger than 65 years. Analysis of median dose intensity demonstrated
no difference between the two groups. Overall objective response was observed in 18% (95% confidence limits 11–29) of elderly
patients (15/82) in comparison with 23% (95% CL 17–32) of patients <65 years of age (31/133 pts). In conclusion, chemotherapy
in elderly patients with advanced colorectal cancer is a safe and effective treatment with acceptable toxicity and comparable
objective response rates.
Received: 6 January 1998 / Accepted: 27 February 1998 相似文献
75.
Chiara Zuccato Marzia Tartari Donato Goffredo Elena Cattaneo Dorotea Rigamonti 《Pharmacological research》2005,52(3):245-251
Treatment of neurodegenerative diseases represents a major challenge for the pharmaceutical industry. Key to developing novel and efficacious therapeutics is the discovery of new druggable targets. Toward this aim, the current drug discovery process is strongly relying on the improved understanding of disease mechanisms and on a synergistic approach with chemistry, molecular biology and robotics. In this scenario, we present the case of a newly discovered molecular mechanism that may be of interest for drug discovery programmes in Huntington's disease and other neurodegenerative diseases. 相似文献
76.
Munzone E Nolé F Goldhirsch A Botteri E Esposito A Zorzino L Curigliano G Minchella I Adamoli L Cassatella MC Casadio C Sandri MT 《Clinical breast cancer》2010,10(5):392-397
BackgroundHER2/neu status of tumor cells at metastatic sites in patients with advanced disease may differ from that of the primary tumor. Assessing the presence of target antigens on circulating tumor cells (CTCs) might affect treatment choice.Patients and MethodsFrom June 2007 to October 2008, we collected 23 mL of blood from each of the 76 consecutive patients before and during chemotherapy to determine CTC numbers and HER2 overexpression. CTCs were isolated with the CellSearch System® (Veridex, LLC; Raritan, NJ) and fluorescently stained with the Epithelial Cell Kit®. Tumor Phenotyping Reagent® was used to investigate HER2/neu overexpression.ResultsConcordance of HER2 status between the primary tumor and CTCs was 86% (49 out of 57 patients) at baseline and 82% (50 out of 61 patients) in the treatment samples. HER2 overexpression in CTCs was acquired in 8 out of 45 patients (18%) and lost in 3 out of 16 patients (19%) during a treatment containing trastuzumab. The overall discordance rate between the primary tumor and CTCs was 18% (11 out of 61 patients). Patients with HER2 overexpression in CTCs had poorer progression-free survival compared with those without CTCs or with HER2? CTCs (log-rank P =.036).ConclusionInformation on the presence or absence of HER2 overexpression can be obtained in CTCs. Larger trials are needed to evaluate the activity of HER2-targeted therapy in patients with acquired HER2 overexpression in CTCs. 相似文献
77.
Metformin Decreases Circulating Androgen and Estrogen Levels in Nondiabetic Women With Breast Cancer
Carlo Campagnoli Franco Berrino Elisabetta Venturelli Chiara Abbà Nicoletta Biglia Tiziana Brucato Patrizia Cogliati Saverio Danese Michela Donadio Gianna Zito Patrizia Pasanisi 《Clinical breast cancer》2013,13(6):433-438
IntroductionDiabetic patients treated with metformin have a lower risk of developing BC or a better BC prognosis. Metformin might reduce cancer growth through direct antiproliferative effects or through indirect mechanisms, particularly the reduction of insulin. In a randomized study on nondiabetic BC patients in natural menopause with high testosterone levels, we observed a significant decrease in insulin and in testosterone levels with metformin 1500 mg/d compared with 1000 mg/d. We present the results of a new analysis of our study on the effect of metformin on the bioavailability of sex hormones.Patients and MethodsOne hundred twenty-four eligible women were initially invited to take metformin 500 mg/d for 3 months. The 108 women who completed the first 3 months continued the study using 1000 mg/d for 1 month. The women were then randomized into 2 groups, and, for the subsequent 5 months, 1 group increased the dose to 1500 mg/d, and the other group continued with 1000 mg/d.ResultsNinety-six women completed the study, 43 receiving metformin 1500 mg/day, and 53 receiving 1000 mg/day. The women receiving 1500 mg/d showed a greater and significant reduction of free testosterone (?29%) and estradiol (?38%), a borderline significant reduction of estrone and insulin-like growth factor-1, and a nonsignificant reduction of androstenedione. They also showed a nonsignificant increase of dehydroepiandrosterone sulfate.ConclusionMetformin does not interfere with the production of dehydroepiandrosterone sulfate. Besides, it decreases estradiol levels, basically through the reduction of testosterone. These hormonal changes might have clinical relevance. 相似文献
78.
Hassan Javed Elisa Zanchi Fabiana DIsanto Chiara Bert Domenico Ferrero Massimo Santarelli Federico Smeacetto 《Materials》2022,15(17)
This study presents results on the development of strontium oxide (SrO) containing glass sealants used to join Crofer22APU to yttria-stabilized zirconia (3YSZ), in which the main glass components, that is, silicon oxide (SiO2), strontium oxide (SrO), calcium oxide (CaO) and aluminum oxide (Al2O3), have been varied appropriately. Certain properties, such as the crystallization behavior, the coefficient of thermal expansion, adhesion, and reactivity of the sealants in contact with Crofer22APU, have been reviewed and discussed. The optimized glass composition (with CTE in the 9.8–10.3 × 10−6 K−1 range) results in a good joining behavior by hindering the formation of undesirable strontium chromate (SrCrO4) on contact with the Crofer22APU steel after 1000 h. at 850 °C. High specific resistivity values of about 106 Ohm.cm have been obtained, thus demonstrating good insulating properties at 850 °C under an applied voltage of 1.6 V. A negligible degradation in the electrical resistivity trend was measured during the test up to 1000 h, thus excluding the presence of detrimental reactions of the glass-ceramic sealant in contact with Crofer22APU under a dual atmosphere, as confirmed using SEM-EDS post-mortem analyses. 相似文献
79.
lvaro Lpez-Valias Laura Baioni Lorena Crdoba Ayub Darji Chiara Chiapponi Joaquim Segals Llilianne Ganges Jos I. Núez 《Viruses》2022,14(9)
Swine influenza viruses (SIV) produce a highly contagious and worldwide distributed disease that can cause important economic losses to the pig industry. Currently, this virus is endemic in farms and, although used limitedly, trivalent vaccine application is the most extended strategy to control SIV. The presence of pre-existing immunity against SIV may modulate the evolutionary dynamic of this virus. To better understand these dynamics, the viral variants generated in vaccinated and nonvaccinated H3N2 challenged pigs after recovery from a natural A(H1N1) pdm09 infection were determined and analyzed. In total, seventeen whole SIV genomes were determined, 6 from vaccinated, and 10 from nonvaccinated animals and their inoculum, by NGS. Herein, 214 de novo substitutions were found along all SIV segments, 44 of them being nonsynonymous ones with an allele frequency greater than 5%. Nonsynonymous substitutions were not found in NP; meanwhile, many of these were allocated in PB2, PB1, and NS1 proteins. Regarding HA and NA proteins, higher nucleotide diversity, proportionally more nonsynonymous substitutions with an allele frequency greater than 5%, and different domain allocations of mutants, were observed in vaccinated animals, indicating different evolutionary dynamics. This study highlights the rapid adaptability of SIV in different environments. 相似文献
80.
Giulia Franzoni Susanna Zinellu Elisabetta Razzuoli Lorena Mura Chiara G. De Ciucis Livia De Paolis Tania Carta Antonio G. Anfossi Simon P. Graham Bernardo Chessa Silvia Dei Giudici Annalisa Oggiano 《Viruses》2022,14(10)
Toll-like receptor 2 (TLR2) ligands are attracting attention as prophylactic and immunopotentiator agents against pathogens, including viruses. We previously reported that a synthetic diacylated lipopeptide (Mag-Pam2Cys_P48) polarized porcine macrophages towards a proinflammatory antimicrobial phenotype. Here, we investigated its role in modulating monocyte-derived macrophage (moMΦ) responses against African swine fever virus (ASFV), the etiological agent of one of the greatest threats to the global pig industry. Two ASFV isolates were compared: the attenuated NH/P68 and the virulent 26544/OG10. No effect on virus infection nor the modulation of surface markers’ expression (MHC I, MHC II DR, CD14, CD16, and CD163) were observed when Mag-Pam2Cys_P48 treated moMΦ were infected using a multiplicity of infection (MOI) of 1. Mag-Pam2Cys_P48 treated moMΦ released higher levels of IL-1α, IL-1β, IL-1Ra, and IL-18 in response to infection with NH/P68 ASFV compared to 26544/OG10-infected and mock-infected controls. Surprisingly, when infected using a MOI of 0.01, the virulent ASFV 26544/OG10 isolate replicated even slightly more efficiently in Mag-Pam2Cys_P48 treated moMΦ. These effects also extended to the treatment of moMΦ with two other lipopeptides: Mag-Pam2Cys_P80 and Mag-Pam2Cys_Mag1000. Our data suggested limited applicability of TLR2 agonists as prophylactic or immunopotentiator agents against virulent ASFV but highlighted the ability of the virulent 26544/OG10 to impair macrophage defenses. 相似文献